FDA cites Indian ingredients supplier for deleting records

Taking stock of the drug industry, from the lab to the medicine chest

February 10, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | FDA cites Indian ingredients supplier for deleting records The FDA warning highlights ongoing anxiety over quality control among pharmaceutical manufacturers in India. By Ed Silverman Opinion: The FDA's misguided thinking on antibiotics The FDA and industry focus on killing bugs in test tubes. That's not the right way to think about antibiotics. By Diana M. Zuckerman and John H. Powers III STAT+ | Two biotechs say they're using AI to conjure drugs from scratch. Their documents suggest otherwise  AI drug discovery claims face scrutiny. Are Absci and Generate Biomedicines truly innovating, or is it biotech hype? Can AI build a drug from scratch? By Brittany Trang Adobe STAT+ | Opinion: The life sciences industry needs a new approach As life science consultants, we've noticed many of the challenges clients face in the market originate in how they perceive their role in patients' lives. By Noël Theodosiou and Yogi Hendlin

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser